GH/IGF-1 effect on IHL among people with or without GHD I recall there were a discussion while ago about growth hormone deficiency among HIV patients(1/3 of PLWH are suffering from growth hormone deficiency) Tesamorelin's stimulation of pituitary gland resulting in natural increased levels of GH and insulin like growth hormone factor-1 would work among HIV patients with NAFLD/NASH but not people with normal growth hormone levels. Same is true about obese people they also have suppressed level of GH and high prevalence of NAFLD/NASH.
Well this study published yesterday is stating that even people without GH disorders the increased level of GH/IGF-1 will decrease the liver fat. Point is with or without GHD( GHD is more common among PLWH and obese people) Tesamorelin which increases the GH/IGF-1 production can reduce the liver fat and prevent NAFLD/NASH not only in obese or HIV patients
but none obese and general population.
"GH/IGF-I axis activity impacts hepatic lipid and phosphate metabolism in individuals without disorders in GH secretion. Lower GH-axis activity is associated with higher IHL(intra hepatic lipid)and an unfavourable lipid composition, probably mediated by changes in hepatic energy metabolism."
https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/clinem/dgad206/7146123